Saturday 17 October 2026 Export CYTK’s income statement to Excel — free account

Cytokinetics, Incorporated

Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024. In the quarter to June 2026, revenue fell 57.1%, EPS fell 33.9%, free cash flow fell 24.0% and total debt rose 57.7%, each against the same quarter a year earlier.

61.95 1.97 −3.08%

Follow CYTK

Alert me

Market cap: $8.9B
P/E: 0.0×
Fwd P/E: −11.1×
Dividend yield: —
F-score: 2/9
Altman Z: −1.98
Beneish M: −0.44
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 50.62

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	4	9	2	2	11	7	9	8	8	4	7	2

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 8,890.00

Revenue 67.67

Net Income (894.00)

Free Cash Flow (580.71)

Net Debt (18.60)

Current Ratio 6.66

Debt/Equity (6.61)

P/E ratio 0.00

Fwd P/E (11.10)

P/S ratio 120.92

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 7.73%

Next Y EPS Growth 25.03%

Next Y revenue growth 71.06%

Next 5Y EPS Growth 31.75%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 76.52%

10-year low 10-year high

EV/Sales against its own 10 years 77.29%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	615	1,076	882	1,166
Receivables	1	17	18	24
Inventory	—	—	—	0
Other	—	—	—	—
	628	1,108	917	1,208

	2023	2024	2025	Q'26
Payables	22	20	22	21
ST’ Debt	10	12	41	27
Other	11	21	35	34
	103	180	202	181

Compound Annual Growth %

	10y	5y	3y
Sales	11.88%	9.54%	(2.36%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	19	29	—	—	—
’25	2	67	2	18	88
’24	1	0	0	17	18
’23	5	1	0	2	8
’22	1	89	3	2	95
’21	7	3	5	56	70
’20	4	4	42	7	56

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(145)	(160)	—	—	—
’25	(132)	(128)	(108)	(143)	(510)
’24	(130)	(99)	(101)	(66)	(396)
’23	(122)	(122)	(96)	(74)	(414)
’22	(27)	(90)	(84)	(98)	(300)
’21	(30)	(29)	(39)	(45)	(143)
’20	(30)	(27)	14	52	9

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(151)	(164)	—	—	—
’25	(137)	(132)	(117)	(148)	(535)
’24	(130)	(101)	(102)	(67)	(400)
’23	(123)	(123)	(96)	(74)	(416)
’22	(28)	(91)	(90)	(101)	(311)
’21	(36)	(38)	(54)	(62)	(191)
’20	(31)	(28)	12	46	(2)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.67)	(1.50)	—	—	—
’25	(1.36)	(1.12)	(2.55)	(1.50)	(6.54)
’24	(1.33)	(1.31)	(1.36)	(1.26)	(5.26)
’23	(1.38)	(1.34)	(1.35)	(1.38)	(5.45)
’22	(1.05)	(0.23)	(1.52)	(1.45)	(4.33)
’21	(0.66)	(0.86)	(0.95)	(0.36)	(2.80)
’20	(0.66)	(0.68)	(0.05)	(0.62)	(1.97)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	6.00	7.00	5.90	5.75	8.00	17.72	29.26	25.98	45.66	29.31	Analyst estimates 2026–2028 Powerpack
	High	12.98	17.20	10.26	14.94	30.14	47.90	55.80	87.58	110.25	70.98
People
People	Employees	127	137	130	156	184	253	409	423	498	673
	Revenue/emp, $m	0.84	0.10	0.24	0.17	0.30	0.28	0.23	0.02	0.04	0.13
Income, $m
Income, $m	Revenue	106	13	32	27	56	70	95	8	18	88
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	16	(128)	(106)	(122)	(127)	(215)	(389)	(526)	(590)	(785)
	EBT margin, %	15.46	(955.94)	(337.41)	(452.93)	(228.00)	(305.72)	(411.21)	(6,988.63)	(3,191.11)	(891.60)
	Net income	16	(128)	(106)	(122)	(127)	(215)	(389)	(526)	(590)	(785)
	Depreciation	1	2	1	1	2	2	6	12	10	10
Per share, $
Per share, $	Revenue	2.66	0.27	0.58	0.47	0.87	0.92	1.05	0.08	0.17	0.73
	Earnings	0.41	(2.59)	(1.95)	(2.11)	(1.97)	(2.80)	(4.33)	(5.45)	(5.26)	(6.54)
	Cash flow	0.93	(2.06)	(1.86)	(1.58)	0.14	(1.85)	(3.33)	(4.29)	(3.54)	(4.25)
	Capex	(0.04)	(0.06)	(0.02)	(0.05)	(0.17)	(0.64)	(0.13)	(0.01)	(0.03)	(0.21)
	Free cash flow	0.89	(2.12)	(1.88)	(1.62)	(0.03)	(2.49)	(3.46)	(4.31)	(3.57)	(4.45)
	Book value	2.36	2.22	0.48	(0.19)	1.76	3.17	(1.20)	(4.00)	(1.21)	(5.49)
	Shares, m	40	49	54	58	65	77	90	97	112	120
Valuation, ×
Valuation, ×	P/E	32.63	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	4.65	32.34	10.92	22.74	24.02	49.76	42.12	1,078.30	285.13	86.68
	P/B	5.25	3.94	13.26	0.00	11.83	14.37	0.00	0.00	0.00	0.00
	EV/Sales	3.47	15.34	5.96	19.34	18.19	45.30	40.30	1,078.65	262.46	89.80
	EV/FCF	10.42	(1.96)	(1.84)	(5.56)	(481.39)	(16.67)	(12.26)	(19.54)	(12.13)	(14.78)
Cash, $m
Cash, $m	Operating cash flow	37	(102)	(101)	(91)	9	(143)	(300)	(414)	(396)	(510)
	Capex	(2)	(3)	(1)	(3)	(11)	(49)	(11)	(1)	(4)	(25)
	Free cash flow	35	(105)	(102)	(94)	(2)	(191)	(311)	(416)	(400)	(535)
Balance, $m
Balance, $m	Working capital	125	242	185	208	443	464	711	525	928	715
	Total debt	30	32	42	134	139	158	611	617	657	1,157
	Net debt	(126)	(237)	(156)	(91)	(325)	(314)	(172)	3	(419)	275
	Shareholders’ equity	94	110	26	(11)	113	244	(108)	(386)	(135)	(660)
Returns, %
Returns, %	ROA	11.53	(54.97)	(42.01)	(48.58)	(30.91)	(31.32)	(41.91)	(57.23)	(52.97)	(55.55)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	20.19	(125.16)	(156.57)	(1,622.88)	(248.50)	(120.54)	(572.15)	212.96	226.00	197.47

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
KRYS Krystal Biotech, Inc.	$9.8B	38.3×	38.6×	+24.14% (above 0%: growing)	+39.10% (above 0%: growing)	+40.14% (above 0%: growing)	94.60%	49.00%	Compare
KYMR Kymera Therapeutics, Inc.	$9.0B	— (loss-making)	— (loss-making)	+466.40% (above 0%: growing)	n/m	+9.97% (above 0%: growing)	100.00%	(116.32%)	Compare
CAI Caris Life Sciences,�Inc.	$9.0B	81.3×	163×	+45.38% (above 0%: growing)	n/m	+8.47% (above 0%: growing)	68.10%	10.21%	Compare
CYTK Cytokinetics, Incorporated	$8.9B	— (loss-making)	— (loss-making)	−57.13% (below 0%: shrinking)	n/m	−24.02% (below 0%: shrinking)	80.46%	(625.95%)
PTGX Protagonist Therapeutics, Inc.	$8.8B	106×	25.0×	+3,749.17% (above 0%: growing)	n/m	+839.65% (above 0%: growing)	100.00%	74.37%	Compare
TGTX TG Therapeutics, Inc.	$8.6B	17.8×	29.4×	+70.27% (above 0%: growing)	−73.68% (below 0%: shrinking)	+427.05% (above 0%: growing)	82.86%	9.02%	Compare
AXSM Axsome Therapeutics, Inc.	$8.5B	— (loss-making)	— (loss-making)	+45.54% (above 0%: growing)	n/m	−2.98% (below 0%: shrinking)	93.79%	(22.73%)	Compare
ARWR Arrowhead Pharmaceuticals, Inc.	$8.3B	— (loss-making)	— (loss-making)	+171.02% (above 0%: growing)	n/m	−15.43% (below 0%: shrinking)	100.00%	(226.03%)	Compare
ABVX Abivax SA Sponsored ADR	$8.1B	— (loss-making)	—	—	n/m	−48.28% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$8.7B	59.8×	34.0×	+70.27%	—	+9.22%	94.20%	4.51%

All 614 Biotechnology stocks →

Cytokinetics, Incorporated (CYTK) key facts

Concern: Cytokinetics, Incorporated reported a net loss of $785.0 million, or a loss of $6.54 per share, for fiscal 2025.
Strength: Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.
Cytokinetics, Incorporated (CYTK) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CYTK traded at $61.95, a market capitalization of $8.9 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 121× sales.
Return on equity was 197.5% and debt-to-equity -6.61.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −1.98 (distress zone) for fiscal 2025.